Day 1 | Day 2 | Short Courses | Download Brochure
TUESDAY, NOVEMBER 3
7:30 am Continental Breakfast Breakout Discussion Sessions
8:30 Chairperson’s Remarks
Christophe J. Echeverri, Ph.D., CEO/CSO, Cenix BioScience GmbH
8:40 Keynote Presentation:
RNAi and Integrated Genomic Approaches to Cancer
David Root, Ph.D., Project Leader, The RNAi Consortium Broad Institute of MIT and Harvard
We have characterized the performance of The RNAi Consortium lentiviral shRNA library, including individual measurements of knockdown for over 60,000 shRNA viruses. These data are presented as well as illustrations of the integration of RNAi and other genomic date to understand cancer cell proliferation and response to therapeutics, as well as other diverse phenotypes.
9:40 Networking Coffee Break in the Exhibit Hall
10:40 High-Throughput Biology Using RNAi arrays
Neil Emans, Ph.D. (formerly Principal Investigator, Institute Pasteur Korea)
RNAi arrays push the performance envelope taking genome wide screening from weeks to less than a day. Enabling the use of image analysis on a large scale for functional screens is one step toward the goal of the integration of super-resolution methods that have molecular detail. A second will be the personalization of genome wide RNAi technology, to move from the bench to a description of the disease level of a patient. This talk will focus on our effort to bring these aspects of RNAi technology forward.
11:10 Tumorigenesis and Clinical Outcome are Determined by Network Transformations in Hepatocellular Carcinoma
John R. Lamb, Ph.D., Scientific Director, Department of Genetics, Rosetta Inpharmatics
Cancer has long been recognized as a disease of genomic instability followed by selection of advantageous changes. We posed the question of whether systems biology approaches can be used to comprehensively reconstruct tumorigenesis as it occurs in patients with hepatocellular carcinoma. The analysis suggests a previously unrecognized degree of structure in tumor samples, connecting widespread somatic copy number aberrations to tumor expression networks and clinical outcome in a cohesive and highly connected whole. The impact of this analysis on target and patient selection will be discussed.
11:40 An Integrated Data Environment for Image Based RNAi Research
Karol Kozak, Ph.D., Database Handling Unit, High Content Screening, Light Microsopy Center, ETH Zurich
Screening for RNAi with a favorable biological effect is at the core of the modern drug discovery process. High Content Screening (HCS) is increasingly used for the automated evaluation of spatio-temporally resolved multiple biochemical and morphological parameters in cellular systems using siRNA. HCS data include comprehensive information about targeted genes and images, as well as their extracted data matrices after acquisition. This presentation will focus on open-source data management solution for integrating, sharing, analysis and processing HCS data using a distributed service-oriented architecture.
12:10 pm RNAi Approach in Guiding the Clinical Trial Design
Holly Yin, Ph.D., Associate Investigator and Head,Cellular Genomics, Translational Genomics Research Institute
Sponsored by
12:40 Luncheon Presentation
RNAi Knockdown Model Generation and Characterization
Christine L. Olsson, Ph.D., Commercialization Scientific Director, Taconic Artemis
Tania Sorg, Ph.D., ICS Technical Director, PhenoPro
Inducible/reversible RNAi technology allows a researcher temporal control of gene expression in vivo and in vitro. Taconic presents its innovative technology for RNAi rodent strain production. Scientists cannot live by strain production alone, thus Taconic and PhenoPro have formed an alliance to offer comprehensive arrays of state-of-the-art mouse phenotyping test panels, addressing most organs and therapeutic areas.
PhenoPro presents its phenotyping platforms covering the nervous system (behavior, cognition, pain and sensory-motricity), cardiac and respiratory functions. PhenoPro has a complete metabolic panel and all phenotypic arrays are associated to clinical chemistry and histopathological analysis.
With the state of the art RNAi strain produced by Taconic and PhenoPro’s tools, know-how and scientific expertise in advanced mouse phenotyping-based translational medicine, we offer our clients improved biopharmaceutical drug discovery & development.
2:00 Close of Conference
Day 1 | Day 2 | Short Courses